Ambrx Appoints Renu Vaish, M.Sc., as Chief Regulatory Officer to Lead Regulatory Affairs
SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc. (“Ambrx” or the “Company”) (NASDAQ: AMAM), today announced the appointment of Renu Vaish, M.Sc., as Chief Regulatory Officer. Ms. Vaish will be responsible for overseeing and designing the Company’s global regulatory strategy and will report to the Company’s President and Chief Executive Officer, Daniel J. O’Connor.
Ms. Vaish is an experienced leader in U.S. and global regulatory affairs with extensive experience in oncology drug development ranging from pre-clinical to commercial products in many fields, including prostate and breast cancer. She has held senior regulatory leadership positions at Celgene, Merck and Kite Pharma, as well as other biopharma companies. Most recently, she served as the Senior Vice President, Regulatory Affairs at SpringWorks Therapeutics.
Ms. Vaish brings a strong business acumen and technical ability that will be used to leverage strategic thinking into innovative regulatory solutions at Ambrx. She has a demonstrated ability to adapt quickly in challenging and dynamic environments while leading through periods of organizational growth. Her successful track record of achieving results in a variety of diverse, global regulatory and quality settings will be a significant asset to Ambrx.
Ms. Vaish has a Master of Science in Regulatory Affairs and Health Policy from the Massachusetts College of Pharmacy and Health Sciences and a Bachelor of Science in Cell and Molecular Biology, from Concordia University.
“Renu’s extensive regulatory background and her experience in designing global regulatory strategy for multiple biopharma companies will be an important asset to Ambrx as we progress our core ADC product candidates, ARX788 and ARX517, through the clinical trial process,” said Mr. O’Connor.
Renu Vaish, M.Sc., added: “I am excited and honored to be joining Ambrx at this time and very much look forward to working with my colleagues on the continued development of potentially transformative medicines for patients.”
In connection with her appointment, Renu Vaish received a one-time inducement award of 2,600,000 ordinary share options, or the equivalent of 371,428 American Depository Shares, which vest over three years. The Company approved the award as an inducement material to Ms. Vaish entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).
About Ambrx Biopharma Inc.
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. In addition, Ambrx has preclinical and clinical collaborations with multiple partners on drug candidates generated using Ambrx technology. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx’s protein engineering technology. For more information, please visit www.ambrx.com. Ambrx routinely posts information that may be important to investors on its website.
Forward-Looking Statements
This press release includes certain “forward-looking statements” intended to qualify for the “safe harbor” from liability established by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements may be identified by the words “intend,” “plan,” and similar expressions. Forward-looking statements are based on Ambrx’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the continuing impact of the COVID-19 pandemic and other public health-related risks and events on Ambrx’s business, operations, strategy, goals and anticipated milestones; Ambrx’s ability to execute on its strategy including with respect to the timing of its R&D efforts, initiation of clinical trials and other anticipated milestones; risks associated with development and marketing approval of novel therapeutics, including potential delays in clinical trials and regulatory submissions and the fact that future clinical trial results/data may not be consistent with interim, initial or preliminary results/data or results/data from prior preclinical studies or clinical trials; Ambrx’s ability to fund operations as anticipated; and the additional risks and uncertainties set forth more fully under the caption “Risk Factors” in Ambrx’s Quarterly Report on Form 10-Q filed with the SEC on May 11, 2023, and elsewhere in Ambrx’s filings and reports with the SEC, including the prospectus supplement to be filed in connection with the Offering. Forward-looking statements contained in this press release are made as of this date, and Ambrx undertakes no duty to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.
Contacts
INVESTORS
Mike Moyer
LifeSci Advisors
617-308-4306
mmoyer@lifesciadvisors.com
MEDIA
Mike Tattory
Account Supervisor
LifeSci Communications
media@ambrx.com
Source: Ambrx Biopharma Inc.
